News

A reduced glucocorticoid dosing regimen for inducing disease remission in people with ANCA-associated vasculitis (AAV) may be associated with a higher risk of poor disease outcomes in those with severe disease, compared with the standard-dose regimen. That’s according to a real-world study in France and Luxembourg that involved people…

Q32 Bio is delaying the start of a planned Phase 2 clinical trial designed to test its ADX-097 therapy candidate in people with ANCA-associated vasculitis (AAV). The trial had been expected to begin in 2025. While details on that planned Phase 2 trial in AAV patients had…

Enrollment is now open for a small clinical trial designed to test dose-escalating doses of experimental cell therapy NKX019 in people with ANCA-associated vasculitis (AAV) and other autoimmune disorders. Called Ntrust-2, the study will assess the therapy’s safety and ability to promote long-term disease remissions in an initial group…

Eosinophilic granulomatosis with polyangiitis (EGPA) should be considered in people with uncontrolled severe asthma and high blood levels of immune cells called eosinophils — a hallmark of the autoimmune disease — according to the findings of a study from Singapore. This rare type of ANCA-associated vasculitis (AAV) was…

Being frail, that is, more vulnerable to health stressors as a result of aging-related biological changes, may put older adults with ANCA-associated vasculitis (AAV) at higher risk of developing severe infections, a study in the U.S. suggests. Being age 75 or older, but not frail, was linked to a…

Most children with granulomatosis with polyangiitis (GPA) have respiratory manifestations including cough and shortness of breath at diagnosis, and these frequently persist or relapse, according to a study in the U.S. involving 13 pediatric patients. Lung abnormalities were detected in nearly all children with available imaging data at diagnosis…

People with ANCA-associated vasculitis (AAV) who carry certain variants in SERPINA1 — a gene that’s been previously linked to the autoimmune disease — may have a six times higher risk of death than those without such variants. That’s according to new data from a single-center study in Brazil, in…

Treatment with rituximab in children with ANCA-associated vasculitis (AAV) is at least non-inferior to the use of cyclophosphamide at inducing disease remission or low disease activity among pediatric patients, according to data from a large international observational study. The researchers noted that rituximab treatment was associated with greater…

People with ANCA-associated vasculitis (AAV) have a higher frequency of thyroid diseases, that is, those that affect the hormone-production function of the thyroid gland, than the general population, a study in China suggests. Being female, having coronary artery disease, which is marked by reduced blood flow in the arteries…

Low blood levels of glial fibrillary acidic protein (GFAP) are linked to more active disease and a higher risk of kidney failure in newly diagnosed ANCA-associated vasculitis (AAV), a study finds. The findings point to GFAP as a potential blood biomarker to predict the course of AAV early and…